Show simple item record

dc.contributor.authorAbu Ammar, Aiman
dc.contributor.authorNasereddin, Abed
dc.contributor.authorEreqat, Suheir
dc.contributor.authorDan-Goor, Mary
dc.contributor.authorJaffe, Charles L.
dc.contributor.authorZussman, Eyal
dc.contributor.authorAbdeen, Ziad
dc.date.accessioned2019-11-17T17:44:20Z
dc.date.available2019-11-17T17:44:20Z
dc.date.issued2018-11-27
dc.identifier.citationTY - JOUR AU - Abu Ammar, Aiman AU - Nasereddin, Abedelmajeed AU - Ereqat, Suheir AU - Dan-Goor, Mary AU - Jaffe, Charles AU - Zussman, Eyal AU - Abdeen, Ziad PY - 2018/11/27 SP - T1 - Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis. Full-text: https://rdcu.be/bb6AP VL - DO - 10.1007/s13346-018-00603-0 JO - Drug Delivery and Translational Research ER -en_US
dc.identifier.issn2190-3948
dc.identifier.urihttps://dspace.alquds.edu/handle/20.500.12213/4921
dc.description.abstractCutaneous leishmaniasis (CL) is an infectious, parasitic disease caused by the protozoan Leishmania. Amphotericin B (AMB) is a macrolide polyene antibiotic presenting potent antifungal and antileishmanial activity, but due to poor water solubility at physiological pH, side effects, and toxicity, its therapeutic efficiency is limited. In the present study, poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) loaded with AMB were generated to reduce drug toxicity and facilitate localized delivery over a prolonged time. AMB NPs were characterized for particle size, zeta potential, polydispersity index, and degree of aggregation. In vitro assessments demonstrated its sustained activity against Leishmania major promastigotes and parasite-infected macrophages. A single intralesional administration to infected BALB/c mice revealed that AMB NPs were more effective than AMB deoxycholate in terms of reducing lesion area. Taken together, these findings suggest thatAMB NPs improve AMB delivery and can be used for local treatment of CL.en_US
dc.description.sponsorshipThis research was funded by the GIP program of the Deutsche Forschungsgemeinschaft (DFG) German Research Foundation. EZ wish to acknowledge the financial support of the RBNI-The Russell Berrie Nanotechnology Institute at the Technion. CLJ holds the Michael and Penny Feiwel Chair of Dermatology.en_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.subjectAmphotericin Ben_US
dc.subjectNanoparticlesen_US
dc.subjectSustained releaseen_US
dc.subjectCutaneous leishmaniasisen_US
dc.subjectTopical therapyen_US
dc.titleAmphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasisen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record